Classification and hearing evolution of patients with sudden sensorineural hearing loss.
The aim of this study was to analyze clinical aspects, hearing evolution and efficacy of clinical treatment of patients with sudden sensorineural hearing loss (SSNHL). This was a prospective clinical study of 136 consecutive patients with SSNHL divided into three groups after diagnostic evaluation: patients with defined etiology (DE, N = 13, 10%), concurrent diseases (CD, N = 63, 46.04%) and idiopathic sudden sensorineural hearing loss (ISSHL, N = 60, 43.9%). Initial treatment consisted of prednisone and pentoxifylline. Clinical aspects and hearing evolution for up to 6 months were evaluated. Group CD comprised 73% of patients with metabolic decompensation in the initial evaluation and was significantly older (53.80 years) than groups DE (41.93 years) and ISSHL (39.13 years). Comparison of the mean initial and final hearing loss of the three groups revealed a significant hearing improvement for group CD (P = 0.001) and group ISSHL (P = 0.001). Group DE did not present a significant difference in thresholds. The clinical classification for SSNHL allows the identification of significant differences regarding age, initial and final hearing impairment and likelihood of response to therapy. Elevated age and presence of coexisting disease were associated with a greater initial hearing impact and poorer hearing recovery after 6 months. Patients with defined etiology presented a much more limited response to therapy. The occurrence of decompensated metabolic and cardiovascular diseases and the possibility of first manifestation of auto-immune disease and cerebello-pontine angle tumors justify an adequate protocol for investigation of SSNHL.
Penido
N O
NO
Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil. nopenido@terra.com.br
Cruz
O L M
OL
Zanoni
A
A
Inoue
D P
DP
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D004359:Drug Therapy, Combination; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D014665:Vasodilator Agents; D010431:Pentoxifylline; D011241:Prednisone